At this meeting, experts who have significant experience with managing neurosarcoidosis will gather to share their latest observations, then participate in a planning retreat to design a program to move the field forward. The outcome of this meeting is expected to be a proposal to the NeuroNEXT network for a study that will refine biomarkers that could be used in a future randomized therapeutic trial, and prove that this condition can be diagnosed and formally studied.
Location:
Eric P. Newman Education Center (EPNEC)
Washington University in St Louis
Date:
Friday, July 24th, 2015
Time:
8:15 am to Noon
Speaker and Topics:
David B Clifford, MD – Washington University in St Louis
Convener, Moderator
Wonder Drake, MD – Vanderbilt University
Pathophysiology of Systemic Sarcoidosis
Barney Stern, MD – University of Maryland
NIH/NHLBI Workshop/NIH Alternatives for funding
Jeffrey Gelfand, MD – University of California San Francisco
Diagnostic challenges, trial design
Carlos Pardo-Villamizar, MD – Johns Hopkins
Hopkins experience, CSF biomarkers
Dr. Albert Levin – Henry Ford Hospital, Detroit
Genetics of sarcoid and neurosarcoidosis
Amy Pruitt, MD – University of Pennsylvania
Neurosarcoid therapy alternatives
Background:
Neurosarcoidosis is one of the most frequent inflammatory brain disorders. Its biology has been little investigated, and no randomized treatment trial has ever been undertaken to design optimal therapy. There are no NIH grants focused on this disorder.
This event has passed.